MedPath

Evaluation of Vitamin B6 (pyridoxine) Effect on symptoms and quality of life in patients with irritable bowel syndrome (IBS)

Phase 2
Conditions
Irritable bowel syndrome.
Irritable bowel syndrome
Registration Number
IRCT20211226053534N2
Lead Sponsor
Islamic Azad University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
60
Inclusion Criteria

Newly diagnosed patients with Irritable Bowel Syndrome (IBS) according to the Rome IV criteria
Age from 18 to 65 years old

Exclusion Criteria

Personal History of malignant diseases of the gastrointestinal tract, Celiac disease, Lactose intolerance, Diverticulitis, Gastrointestinal infection, Hypothyroidism and hyperthyroidism
Presence of other diseases during colonoscopy in individuals over 50 years of age
Pregnancy and lactation
Allergy to the study drug
Lack of consent to participate in the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Irritable bowel syndrome severity. Timepoint: At beginning of the study and four weeks after initiation of the study. Method of measurement: The irritable bowel severity scoring system (IBSSS).
Secondary Outcome Measures
NameTimeMethod
Quality of life in patients with irritable bowel syndrome. Timepoint: At beginning of the study and four weeks after initiation of the study. Method of measurement: Irritable bowel syndrome quality of life questionnaire (IBS-QOL).
© Copyright 2025. All Rights Reserved by MedPath